Abstract
Si306, a pyrazolo[3,4-d]pyrimidine derivative recently identified as promising anticancer agent, has shown favorable in vitro and in vivo activity profile against neuroblastoma (NB) models by acting as a competitive inhibitor of c-Src tyrosine kinase. Nevertheless, Si306 antitumor activity is associated with sub-optimal aqueous solubility, which might hinder its further development. Drug delivery systems were here developed with the aim to overcome this limitation, obtaining suitable formulations for more efficacious in vivo use. Si306 was encapsulated in pegylated stealth liposomes, undecorated or decorated with a monoclonal antibody able to specifically recognize and bind to the disialoganglioside GD2 expressed by NB cells (LP[Si306] and GD2-LP[Si306], respectively). Both liposomes possessed excellent morphological and physio-chemical properties, maintained over a period of two weeks. Compared to LP[Si306], GD2-LP[Si306] showed in vitro specific cellular targeting and increased cytotoxic activity against NB cell lines. After intravenous injection in healthy mice, pharmacokinetic profiles showed increased plasma exposure of Si306 when delivered by both liposomal formulations, compared to that obtained when Si306 was administered as free form. In vivo tumor homing and cytotoxic effectiveness of both liposomal formulations were finally tested in an orthotopic animal model of NB. Si306 tumor uptake resulted significantly higher when encapsulated in GD2-LP, compared to Si306, either free or encapsulated into untargeted LP. This, in turn, led to a significant increase in survival of mice treated with GD2-LP[Si306]. These results demonstrate a promising antitumor efficacy of Si306 encapsulated into GD2-targeted liposomes, supporting further therapeutic developments in pre-clinical trials and in the clinic for NB.
Highlights
Neuroblastoma (NB) is a solid tumor that occurs in the pediatric population and Neuroblastoma (NB) is a solid tumor that occurs in the pediatric population and causes 15% of childhood cancer deaths [1]
The RPMI-1640 and Dulbecco’s Modified Eagle’s Medium (DMEM) culture media, foetal bovine serum (FBS), L-glutamine and Penicillin-Streptomycin were purchased from Euroclone S.p.A. (Milan, Italy)
The results are expressed as mean ratio fluorescence intensity (MRFI) calculated as the MFI of samples incubated with both liposomes, divided by the MFI of control (CTR, no liposomes) cells
Summary
Neuroblastoma (NB) is a solid tumor that occurs in the pediatric population and Neuroblastoma (NB) is a solid tumor that occurs in the pediatric population and causes 15% of childhood cancer deaths [1]. Antibody-conjugated liposomes (called immunoliposomes), which can target antigen-expressing tumor cells, have attracted considerable attention as targeted therapies due to their ability to selectively deliver the encapsulated drug to tumor cells, improving efficacy and reducing toxicity [35]. In this context, the disialoganglioside GD2 expressed by tumors of neuroectodermal origin (e.g., melanoma and NB [36]), and very limited expression on healthy cerebellum and peripheral nerves [37,38], represents a wellestablished target for the design of an active targeting strategy for NB [39–41]. GD2-targeted (GD2-LP[Si306]) liposomes (Figure 1b,c) was here evaluated both in vitro and in a clinically relevant mouse model of NB [49]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.